Affinage

IGF2BP3

Insulin-like growth factor 2 mRNA-binding protein 3 · UniProt O00425

Round 2 corrected
Length
579 aa
Mass
63.7 kDa
Annotated
2026-04-28
130 papers in source corpus 44 papers cited in narrative 44 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IGF2BP3 is an oncofetal RNA-binding protein that functions as a major N6-methyladenosine (m6A) reader, using its KH domains to recognize GG(m6A)C motifs on thousands of mRNA targets and predominantly stabilizing them—including MYC, CDK6, HMGA2, EGFR, PD-L1, and serine synthesis pathway transcripts—thereby promoting proliferation, immune evasion, metabolic reprogramming, and drug resistance across diverse cancers (PMID:29476152, PMID:26974154, PMID:35197058, PMID:40328743). Beyond m6A-dependent stabilization, IGF2BP3 can destabilize specific mRNAs through interaction with ribonucleases XRN2 and the exosome or via recognition of internal m7G modifications, and it regulates alternative splicing in concert with NONO (PMID:26522719, PMID:39198433, PMID:38341127). IGF2BP3 protein turnover is tightly controlled by ubiquitination through multiple E3 ligases (TRIM25, HECTD4, Parkin at K213) counterbalanced by USP11-mediated deubiquitination, while circRNAs (circNFATC3, circNEIL3, circRARS) and the post-translational modification lysine lactylation modulate its stability and RNA-binding activity (PMID:33436560, PMID:37877353, PMID:35031058, PMID:39450426). During normal development, IGF2BP3 is essential for maternal mRNA stability during the zebrafish maternal-to-zygotic transition and cooperates with LIN28B to drive fetal-like B-cell lymphopoiesis, while its aberrant re-expression in adult tissues is a hallmark of MLL-rearranged leukemia and numerous solid tumors (PMID:32127635, PMID:31221665, PMID:34321607).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 1999 High

    The initial characterization of IGF2BP3 as an IGF-II mRNA-binding protein with two RRM and four KH domains that represses IGF-II leader 3 mRNA translation established it as a developmentally regulated post-transcriptional regulator.

    Evidence RNA binding assays, luciferase translational reporter, immunolocalization in human/mouse embryos

    PMID:9891060

    Open questions at the time
    • Endogenous target repertoire beyond IGF-II unknown
    • No structural detail of RNA recognition
    • Mechanism of translational repression not defined
  2. 2014 High

    The discovery that IGF2BP3-containing cytoplasmic granules exclude AGO/miRNAs and shield let-7 target mRNAs (HMGA2, LIN28B) from miRNA-mediated decay revealed a 'safe house' mechanism of mRNA stabilization distinct from direct translational control.

    Evidence Granule fractionation, RIP, let-7 antagomiR experiments, 3′UTR let-7 site deletion, IMP1-KO mouse embryos

    PMID:24703842

    Open questions at the time
    • Composition of safe-house granules not fully defined
    • Whether miRNA exclusion is active or passive unclear
    • Applicability beyond let-7 targets not tested
  3. 2015 High

    Demonstrating that IGF2BP3 can destabilize mRNAs (EIF4E-BP2, MEIS3) by recruiting XRN2 and exosome components overturned the assumption that it exclusively stabilizes targets, revealing context-dependent polarity of its post-transcriptional effects.

    Evidence RNA-seq, RIP-seq, co-IP with ribonucleases, mRNA stability assays, rescue experiments in lung adenocarcinoma

    PMID:26522719

    Open questions at the time
    • What determines stabilization versus destabilization for a given target
    • Whether ribonuclease recruitment requires cofactors
    • Structural basis of XRN2/exosome interaction unknown
  4. 2016 High

    CLIP-seq identification of MYC and CDK6 as direct IGF2BP3 targets in MLL-rearranged B-ALL, combined with in vivo mouse hematopoietic models, established IGF2BP3 as a functionally essential oncogene in leukemia with defined downstream effectors.

    Evidence CLIP-seq, 3′UTR reporters, mouse BM transplant, knockdown in B-ALL lines

    PMID:26974154

    Open questions at the time
    • Mechanism of IGF2BP3 re-activation in MLL-rearranged leukemia not resolved
    • Relative contribution of MYC versus CDK6 to leukemogenesis not separated
    • Translational versus stability regulation on these targets not distinguished
  5. 2018 High

    The landmark identification of IGF2BP1/2/3 as a new class of m6A readers that stabilize thousands of m6A-marked mRNAs via their KH domains unified prior observations under an epitranscriptomic framework and distinguished IGF2BPs from decay-promoting YTHDF readers.

    Evidence m6A-seq, PAR-CLIP, RIP, KH domain mutagenesis, MYC mRNA stability assays

    PMID:29476152

    Open questions at the time
    • How KH domains specifically recognize m6A versus unmethylated RNA structurally undefined
    • Whether all four KH domains contribute equally unknown
    • Relative m6A-dependent versus m6A-independent binding proportions unquantified
  6. 2018 High

    Crystal structure of the RRM1-RRM2 tandem revealed that only RRM1 contacts RNA via a dinucleotide recognition mode, with a unique inter-domain orientation, providing the first atomic-resolution view of IGF2BP3-RNA recognition.

    Evidence X-ray crystallography with biochemical RNA-binding validation

    PMID:30135093

    Open questions at the time
    • No structure of KH domains or full-length protein
    • How RRM and KH domains cooperate on a single mRNA unknown
    • Structure of m6A-bound complex not determined
  7. 2019 High

    LIN28B and IGF2BP3 were shown to physically interact and co-stabilize thousands of mRNAs in fetal B-cell progenitors, jointly driving fetal-like lymphopoiesis more efficiently than either factor alone, revealing a cooperative post-transcriptional program in normal hematopoiesis.

    Evidence Proteomics, in situ analysis, CLIP/RIP-seq, in vivo mouse HSPC transplantation, scRNA-seq

    PMID:31221665

    Open questions at the time
    • Whether LIN28B-IGF2BP3 interaction is direct or RNA-mediated not fully resolved
    • Autoregulatory loop mechanism not structurally characterized
    • Relevance to leukemia initiation not tested
  8. 2020 High

    Maternal-specific igf2bp3 deletion in zebrafish causing embryonic lethality through destabilization of maternal mRNAs established that IGF2BP3's mRNA-stabilizing function is essential for vertebrate embryogenesis, not only cancer.

    Evidence Maternal mutant zebrafish, RNA-seq, mRNA half-life measurements, gain- and loss-of-function

    PMID:32127635

    Open questions at the time
    • Whether mammalian maternal-zygotic transition depends on IGF2BP3 similarly untested
    • Specific target mRNAs critical for cytokinesis not identified
    • Redundancy with IGF2BP1/2 in this context unknown
  9. 2021 High

    Genetic deletion of Igf2bp3 in an MLL-Af4 leukemia mouse model significantly extended survival with minimal effect on normal hematopoiesis, validating IGF2BP3 as a therapeutic target and revealing its regulation of Hoxa genes and Ras pathway mRNAs including pre-mRNA splicing.

    Evidence Conditional knockout in mouse MLL-Af4 leukemia model, CLIP-seq, RNA-seq, leukemia-initiating cell assays

    PMID:34321607

    Open questions at the time
    • How IGF2BP3 regulates splicing mechanistically not defined
    • Whether pharmacological inhibition recapitulates genetic deletion unknown
    • Splicing versus stability contribution to leukemogenesis not separated
  10. 2021 High

    Identification of TRIM25 as an E3 ligase that ubiquitinates IGF2BP3 for proteasomal degradation—scaffolded by the circRNA circNDUFB2—established the first ubiquitin-dependent regulatory mechanism controlling IGF2BP3 protein turnover.

    Evidence RIP, RNA pulldown, co-IP, ubiquitination assays, m6A analysis, in vivo assays

    PMID:33436560

    Open questions at the time
    • Specific ubiquitination sites by TRIM25 not mapped
    • Whether other circRNAs similarly scaffold E3 ligases for IGF2BP3 unknown
    • Physiological versus cancer-specific relevance of this pathway unclear
  11. 2022 High

    Multiple studies converged to define IGF2BP3's ubiquitin regulatory network: HECTD4 and Parkin (ubiquitination at K213 in KH1) promote degradation while USP11 deubiquitinates and stabilizes it, and circRNAs (circNEIL3, circNFATC3) competitively block ubiquitination, establishing IGF2BP3 protein level as a tightly controlled node.

    Evidence Co-IP, mass spectrometry site mapping (K213), in vitro/in vivo ubiquitination assays, circRNA binding competition, xenograft models

    PMID:33594305 PMID:35031058 PMID:37340423 PMID:37877353

    Open questions at the time
    • Hierarchy among E3 ligases in different tissues not established
    • Whether K213 ubiquitination is the sole functional site unknown
    • Interplay between lactylation and ubiquitination at nearby residues not explored
  12. 2022 High

    IGF2BP3's m6A reader function was shown to stabilize PD-L1 mRNA downstream of METTL3, directly linking epitranscriptomic mRNA regulation to tumor immune evasion and providing a mechanistic basis for immune checkpoint resistance.

    Evidence MeRIP-seq, RIP-qPCR, METTL3/IGF2BP3 knockdown, T cell co-culture, mouse xenografts

    PMID:35197058

    Open questions at the time
    • Whether IGF2BP3 stabilizes other immune checkpoint mRNAs not tested
    • Patient response to immunotherapy correlation not established
    • Structural basis of m6A-PD-L1 mRNA recognition unknown
  13. 2023 High

    The discovery that IGF2BP3 preferentially binds internal m7G-modified mRNAs and promotes their degradation (including TP53 mRNA) revealed a second epitranscriptomic reading modality with opposite functional polarity to its m6A reader activity.

    Evidence m7G-modified RNA pull-down, binding assays, dCas13b site-specific targeting, mRNA half-life assays in glioblastoma

    PMID:39198433

    Open questions at the time
    • Structural basis for m7G versus m6A discrimination unknown
    • Genome-wide scope of m7G-dependent destabilization not mapped
    • Whether m6A and m7G marks on the same transcript compete for IGF2BP3 binding untested
  14. 2023 Medium

    CircRARS was found to bind IGF2BP3 KH1-KH2 domains via a specific 12-nt motif, enhancing m6A recognition and recruiting stabilizer proteins HuR, Matrin3, and pAbPC1, defining a circRNA-mediated mechanism that augments IGF2BP3's m6A reader activity.

    Evidence RIP, RNA pulldown, domain mapping, m6A binding assays, identification of GUCUUCCAGCAA binding motif

    PMID:38073586

    Open questions at the time
    • Whether circRARS allosterically changes KH domain conformation or acts as a scaffold uncertain
    • Generalizability of this 12-nt motif to other circRNAs not tested
    • Stoichiometry of the circRARS/IGF2BP3/stabilizer complex unknown
  15. 2024 Medium

    Lysine lactylation of IGF2BP3 was identified as a glycolysis-driven post-translational modification that enhances its mRNA-binding capacity and creates a positive feedback loop with m6A methylation (via SAM availability), connecting metabolic state to epitranscriptomic regulation in drug-resistant HCC.

    Evidence Lactylation assays, RIP, MeRIP, metabolomics, lenvatinib-resistant in vivo models

    PMID:39450426

    Open questions at the time
    • Specific lactylated residues on IGF2BP3 not mapped
    • Whether lactylation competes with ubiquitination at the same lysines unknown
    • Relevance beyond lenvatinib resistance not established
  16. 2024 High

    A CRISPR screen revealed that IGF2BP3 sustains the serine synthesis pathway by stabilizing m6A-marked ATF4, PHGDH, and PSAT1 mRNAs in AML, and combined IGF2BP3 depletion with dietary serine/glycine restriction potently suppressed leukemia while sparing normal hematopoiesis, defining a metabolic vulnerability.

    Evidence CRISPR/Cas9 screen, RIP, mRNA stability, metabolomics, dietary restriction in vivo AML models

    PMID:40328743

    Open questions at the time
    • Whether this metabolic dependency extends to solid tumors unknown
    • Pharmacological IGF2BP3 inhibitor for clinical translation not available
    • Mechanism by which normal HSPCs compensate for IGF2BP3 loss unclear

Open questions

Synthesis pass · forward-looking unresolved questions
  • A full structural understanding of how IGF2BP3 discriminates m6A from m7G modifications, how its six RNA-binding domains cooperate on a single mRNA, and whether selective pharmacological inhibition can recapitulate the therapeutic window seen with genetic deletion remain major open questions.
  • No full-length or KH-domain m6A-bound structure exists
  • No selective small-molecule IGF2BP3 inhibitor reported
  • Rules governing stabilization versus destabilization of individual target mRNAs undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 9 GO:0098772 molecular function regulator activity 4 GO:0045182 translation regulator activity 2
Localization
GO:0005829 cytosol 3 GO:0031410 cytoplasmic vesicle 1
Pathway
R-HSA-8953854 Metabolism of RNA 6 R-HSA-1643685 Disease 4 R-HSA-1430728 Metabolism 3 R-HSA-162582 Signal Transduction 3 R-HSA-392499 Metabolism of proteins 3 R-HSA-1266738 Developmental Biology 2
Partners
ILF3LIN28BNONOPRKNPTBP1TRIM25USP11XRN2

Evidence

Reading pass · 44 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 IGF2BP3 (IMP3) was identified as a member of a family of three IGF-II mRNA-binding proteins (IMPs) that bind the 5' UTR of translationally regulated IGF-II leader 3 mRNA but not the constitutively translated leader 4 mRNA, causing dose-dependent translational repression of IGF-II leader 3 mRNA. The proteins contain two RNA recognition motifs and four KH domains and localize to subcytoplasmic domains in a growth-dependent and cell-specific manner. RNA binding assays, luciferase reporter translational repression assay, immunolocalization, developmental expression analysis in mouse and human embryos Molecular and cellular biology High 9891060
2018 IGF2BP1/2/3 function as a distinct family of m6A readers that recognize the consensus GG(m6A)C sequence on thousands of mRNA transcripts, promoting mRNA stability and storage (e.g., MYC mRNA) in an m6A-dependent manner under normal and stress conditions, in contrast to the decay-promoting YTHDF2 reader. The K homology (KH) domains of IGF2BPs are required for m6A recognition and are critical for their oncogenic functions. m6A-seq, PAR-CLIP, RIP, RNA stability assays, mutagenesis of KH domains, in vitro binding assays, functional cancer cell assays Nature cell biology High 29476152
2018 Crystal structure of IMP3 RRM12 (N-terminal tandem RNA recognition motifs) bound to short RNA sequences revealed that both RRM domains adopt canonical RRM topology with a unique spatial orientation relative to each other compared to other tandem RRM structures. Only RRM1 is directly involved in RNA binding and recognizes a dinucleotide sequence. X-ray crystallography, biochemical RNA-binding characterization RNA (New York, N.Y.) High 30135093
2014 IMP3 (IGF2BP3) RNPs function as cytoplasmic 'safe houses' that protect oncogenic let-7 target mRNAs (including HMGA2 and LIN28B) from miRNA-directed mRNA decay. IMP3-containing granules are depleted of Ago1-4 and miRNAs, IMP3 dose-dependently increases HMGA2 mRNA levels, and let-7 antagomiRs render HMGA2 refractory to IMP3 stabilization. Removal of let-7 target sites eliminates IMP3-dependent stabilization. Transcriptome analysis of cancer data, cytoplasmic granule fractionation, RIP, let-7 antagomiR experiments, deletion of 3'UTR let-7 binding sites, IMP1-deficient mouse embryo analysis Cell reports High 24703842
2016 IGF2BP3 (IMP3) is specifically overexpressed in MLL-rearranged B-ALL and is required for survival of B-ALL cell lines (knockdown causes decreased proliferation and increased apoptosis). CLIP-seq identified oncogenes MYC and CDK6 as direct IGF2BP3 targets regulated via 3'UTR binding elements. Enforced IGF2BP3 expression in murine BM cells enhanced Myc and Cdk6 expression, promoted hematopoietic stem/progenitor cell proliferation, and skewed development to B cell/myeloid lineage. CLIP-seq, knockdown/overexpression in cell lines and mouse BM transplant, 3'UTR reporter assays, mRNA expression analysis The Journal of clinical investigation High 26974154
2016 IMP3 (IGF2BP3) associates with circRNAs to form circRNA-protein complexes (circRNPs) of distinct sizes in mammalian cells. A specific set of IMP3-associated circRNAs was identified by combining RNA-seq of IMP3-co-immunoprecipitated RNA with filtering for circular-junction reads, defining a subfamily of circRNPs. Glycerol gradient centrifugation, polysome gradient fractionation, RNA-seq of immunoprecipitated RNA Scientific reports Medium 27510448
2016 IMP-3 (IGF2BP3) and its protein partners ILF3/NF90 and PTBP1 bind to the 3'UTRs of cyclin D1 and D3 mRNAs and protect them from translational repression induced by miRNA-dependent recruitment of the AGO2/GW182 complex. Knockdown of IMP-3 causes rapid decrease in cyclin protein levels while their mRNAs remain stable and polysome-associated but untranslated. RIP, polysome fractionation, knockdown experiments, protein level analysis International journal of oncology Medium 27840950
2015 IGF2BP3 destabilizes EIF4E-BP2 and MEIS3 mRNAs by interacting with ribonucleases XRN2 and exosome components (co-immunoprecipitation), thereby facilitating eIF4E-mediated translational activation. Depletion of EIF4E-BP2 partially rescues the growth retardation caused by IGF2BP3 knockdown, and IGF2BP3 depletion reduces phosphorylated (active) eIF4E. This was the first demonstration of IGF2BP3 as an RNA-destabilizing factor. RNA-seq, RIP-seq, co-immunoprecipitation with ribonucleases, mRNA stability assays, rescue experiments, analysis of human lung adenocarcinoma tissues Oncogene High 26522719
2017 THADA gene fusion to LOC389473 (located 12 kb upstream of IGF2BP3) does not produce a chimeric protein but instead drives strong overexpression of full-length IGF2BP3 mRNA and protein in thyroid cancer, leading to increased IGF2 translation, activation of IGF1R/PI3K and MAPK signaling, and promotion of cell proliferation, invasion, and transformation. Inhibition of IGF1R blocks growth of IGF2BP3-overexpressing cells and tumors in vitro and in vivo. Whole-transcriptome and whole-genome sequencing, functional cell assays, IGF1R inhibitor treatment, in vivo xenograft Proceedings of the National Academy of Sciences of the United States of America High 28193878
2017 IMP2 and IMP3 (IGF2BP2/3) are specifically overexpressed in triple-negative breast cancer, directly target progesterone receptor (PR) mRNA for destabilization through recruitment of the CCR4-NOT (CNOT1) complex, thereby suppressing transcription of miR-200a (which normally targets IMP2/3), forming a double-negative feedback loop that promotes EMT and metastasis. Knockdown/overexpression, cell invasion/invadopodia assays, mRNA stability assays, identification of CNOT1 complex recruitment, luciferase 3'UTR reporter, miRNA functional assays Cancer letters Medium 29217458
2017 IGF2BP3 directly associates with the deubiquitinase USP10 and attenuates its ability to stabilize p53 protein, promoting lung tumorigenesis. IGF2BP3 silencing increases p53 half-life and protein level and induces G0/G1 cell cycle arrest. Co-immunoprecipitation, protein half-life assays (cycloheximide chase), knockdown/overexpression, flow cytometry cell cycle analysis Oncotarget Medium 29212181
2019 Lin28b directly interacts with Igf2bp3 (proteomics and in situ analyses), and their co-expression in adult HSPCs reactivates fetal-like B-cell development more efficiently than either factor alone. In B-cell progenitors, Lin28b and Igf2bp3 jointly stabilize thousands of mRNAs (including Pax5 and Arid3a) by binding at the same sites, and Igf2bp3 mRNA itself is stabilized in an autoregulatory loop. Single-cell RNA-seq, proteomics, in situ analysis, CLIP/RIP-seq, in vivo mouse hematopoietic transplantation Genes & development High 31221665
2020 Igf2bp3 is an essential regulator of maternal mRNA stability in zebrafish. Depletion of maternal igf2bp3 destabilizes maternal mRNAs prior to maternal-to-zygotic transition and causes severe developmental defects including abnormal cytoskeleton organization and cell division, while oogenesis and maternal mRNA levels in unfertilized eggs are normal. Igf2bp3 overexpression enhances stability of its target maternal mRNAs, and depletion or excess Igf2bp3 both impair embryogenesis. Maternal-specific mutant zebrafish, RNA-seq, Gene ontology analysis, mRNA stability assays, gain- and loss-of-function Communications biology High 32127635
2020 DMDRMR (a lncRNA) binds IGF2BP3 to enhance its m6A-dependent activity on specific target mRNAs including CDK4, COL6A1, LAMA5, and FN1, stabilizing these transcripts and promoting G1-S transition and cell proliferation in clear cell renal cell carcinoma. RIP, RNA pulldown, m6A-seq, mRNA stability assays, functional cell and in vivo tumor assays Cancer research Medium 33293428
2021 IGF2BP3 is critical for MLL-Af4-mediated leukemogenesis; deletion of Igf2bp3 significantly increases survival of mice with MLL-Af4-driven leukemia with minimal impact on baseline hematopoiesis. IGF2BP3 regulates a posttranscriptional operon including Hoxa locus genes and Ras pathway genes, controlling both steady-state mRNA levels and pre-mRNA splicing. Conditional genetic deletion in mouse leukemia model, survival analysis, leukemia-initiating cell functional assays, RNA-seq, CLIP-seq Leukemia High 34321607
2021 circNDUFB2 acts as a scaffold to enhance the interaction between E3 ubiquitin ligase TRIM25 and IGF2BPs (including IGF2BP3), forming a TRIM25/circNDUFB2/IGF2BPs ternary complex that facilitates ubiquitination and proteasomal degradation of IGF2BPs; this effect is enhanced by m6A modification of circNDUFB2. RIP, RNA pulldown, co-immunoprecipitation, ubiquitination assays, m6A modification analysis, in vitro and in vivo functional assays Nature communications High 33436560
2022 METTL3-mediated m6A modification of PD-L1 mRNA is recognized by IGF2BP3, which stabilizes PD-L1 mRNA in breast cancer cells, promoting tumor immune escape. METTL3 knockdown abolishes m6A modification and reduces PD-L1 mRNA stabilization; IGF2BP3 knockdown or METTL3 inhibition enhances anti-tumor T cell activity both in vitro and in vivo. MeRIP-seq, epitranscriptomic microarray, MeRIP-qPCR, RIP-qPCR, mouse xenograft models, tissue microarray Molecular cancer High 35197058
2022 The m6A reader IGF2BP3 enhances stability of m6A-modified RCC2 mRNA in an m6A-dependent manner in acute myeloid leukemia cells. IGF2BP3 knockdown dramatically suppresses AML cell survival, reduces proliferation, impairs apoptosis resistance, and attenuates leukemic capacity in vitro and in vivo. RIP, mRNA stability assays, m6A-dependent binding assays, knockdown/overexpression, in vivo mouse AML model Experimental & molecular medicine Medium 35217832
2022 IMP3 (IGF2BP3) promotes prostate cancer metastasis by physically binding HDAC4 mRNA and enhancing its stability, thereby activating ERK signaling and inducing EMT. This is one of two parallel axes by which hsa_circ_0003258 promotes metastasis, the other being miR-653-5p sponging. RNA pulldown, RIP, Western blot, rescue experiments, in vitro and in vivo metastasis assays Molecular cancer Medium 34986849
2022 IGF2BP3 desensitizes lung adenocarcinoma cells to ferroptosis in an m6A reading domain-dependent manner by binding m6A-methylated mRNAs encoding anti-ferroptotic factors (GPX4, SLC3A2, ACSL3, FTH1), stabilizing these transcripts and sustaining anti-ferroptotic protein levels. m6A reader domain mutagenesis, RIP, mRNA stability assays, ferroptosis markers measurement, clinical specimen correlation Materials today. Bio Medium 36457846
2022 circNEIL3 stabilizes IGF2BP3 protein by preventing HECTD4-mediated ubiquitination of IGF2BP3, thereby protecting its oncogenic function in glioma. Additionally, circNEIL3 is packaged into exosomes by hnRNPA2B1 and delivered to tumor-associated macrophages where it similarly stabilizes IGF2BP3 to promote immunosuppressive polarization. RNA pulldown, mass spectrometry, RIP, luciferase reporter, co-immunoprecipitation, ubiquitination assays, exosome characterization Molecular cancer Medium 35031058
2022 TRIM25 E3 ubiquitin ligase promotes ubiquitination and degradation of IGF2BP3, and this process is competitively inhibited by circNFATC3 which binds IGF2BP3 in the cytoplasm, preventing TRIM25-mediated ubiquitination and thereby enhancing IGF2BP3 stability and its regulatory activity on CCND1 mRNA in gastric cancer. RIP, RNA-FISH/IF, co-immunoprecipitation, ubiquitin assays, rescue experiments, in vivo tumor model Journal of translational medicine Medium 37340423
2023 IGF2BP3 recognizes m6A-modified minichromosome maintenance complex component MCM5 mRNAs to stabilize them, subsequently upregulating MCM5 protein, which competitively inhibits SIRT1-mediated deacetylation of Notch1 intracellular domain (NICD1), stabilizing NICD1 and overactivating Notch signaling to induce partial EMT in lung adenocarcinoma. RIP, MeRIP-seq, mRNA stability assays, co-immunoprecipitation, SIRT1 deacetylation assays, functional EMT assays, clinical specimen analysis Advanced science Medium 37171793
2023 IGF2BP3 stabilizes COX6B2 mRNA by binding to its 3'-UTR in an m6A-dependent manner, increasing oxidative phosphorylation (OXPHOS) activity, and thereby driving acquired resistance to EGFR tyrosine kinase inhibitors. The IGF2BP3-COX6B2 axis also regulates nicotinamide metabolism to further alter OXPHOS and promote resistance. RIP, MeRIP analysis, mRNA stability assays, OXPHOS metabolic assays, siRNA knockdown, patient-derived xenograft model, OXPHOS inhibitor treatment Cancer research High 37061993
2023 circRARS binds to the KH1-KH2 domains of IGF2BP3 (via a 12-nt sequence GUCUUCCAGCAA) to enhance IGF2BP3's m6A modification recognition activity, and the IGF2BP3/circRARS complex recruits stabilizer proteins HuR, Matrin3, and pAbPC1 to increase mRNA stability of target genes (CAPN15, CD44, HMGA2, TNRC6A, ZMIZ2) in an m6A-dependent manner. RIP, RNA pulldown, domain mapping, m6A binding assays, functional in vitro and in vivo assays, identification of specific binding sequence Clinical and translational medicine Medium 38073586
2023 Parkin E3 ubiquitin ligase directly interacts with IGF2BP3 and promotes its proteasomal degradation by ubiquitinating it; the ubiquitination site was mapped to K213 in the first KH domain of IGF2BP3. IGF2BP3 K213 mutation abolishes its oncogenic m6A reader function and inactivates PI3K and MAPK signaling in cervical cancer. Co-immunoprecipitation, in vivo and in vitro ubiquitination assays, mass spectrometry ubiquitination site mapping, RNA-IP, xenograft mouse model Clinical and translational medicine High 37877353
2023 USP11 deubiquitinase directly interacts with IGF2BP3 and protects it from proteasomal degradation via deubiquitination, as demonstrated by co-immunoprecipitation and ubiquitination assays. IGF2BP3 overexpression reverses the decrease in colorectal cancer cell proliferation, migration, and invasion caused by USP11 knockdown. Co-immunoprecipitation, ubiquitination assays, Western blotting, rescue experiments, in vivo tumor assays American journal of translational research Medium 33594305
2023 IGF2BP3 promotes mRNA degradation through binding internal m7G-modified mRNAs. IGF2BP family proteins preferentially bind internal mRNA m7G, but with distinct functional consequences: IGF2BP3 binding promotes degradation of m7G target transcripts (including TP53 mRNA at its 3'UTR in glioblastoma), whereas IGF2BP1 prefers m6A to stabilize transcripts. Modulating IGF2BP3 or site-specific m7G targeting via dCas13b affects TP53 mRNA half-life, cancer progression, and chemosensitivity. m7G-modified RNA pull-down, binding assays, mRNA stability (half-life) assays, dCas13b site-specific targeting, functional cancer cell assays Nature communications High 39198433
2023 IGF2BP3 stabilizes EGFR mRNA in an m6A-dependent manner (cooperating with METTL14) and promotes EGFR pathway activation and cetuximab resistance in colorectal cancer. RIP, MeRIP, mRNA stability assays, functional cell and in vivo assays, clinical specimen analysis Cell death & disease Medium 37658049
2023 IGF2BP3 binds SLIT2 mRNA and destabilizes m6A-methylated SLIT2 mRNA, impairing SLIT2/ROBO1 signaling and consequently activating PI3K/AKT and MEK/ERK pathways to promote triple-negative breast cancer migration and invasion. RIP, mRNA stability assays, m6A modification analysis, functional migration/invasion assays, in vivo metastasis model FASEB journal Medium 36250924
2023 IGF2BP3 promotes myocardial regeneration by binding and stabilizing MMP3 mRNA through m6A modification interaction. IGF2BP3 expression progressively decreases postnatally but is re-induced after cardiac injury. MMP3 acts as a downstream effector of IGF2BP3 to regulate cardiomyocyte proliferation, and IGF2BP3 promotes cardiac function recovery after myocardial infarction in mice. Gain- and loss-of-function in vitro and in vivo (mouse MI model), RIP, mRNA stability assays, m6A analysis Cell death discovery Medium 37188676
2023 IGF2BP3 synergizes with NONO to promote exon 6 skipping in DLG1 pre-mRNA in an m6A-dependent manner, and IGF2BP3 disrupts the binding of RBM14 to NONO, thereby relieving RBM14's inhibition of NONO-mediated alternative splicing in gallbladder cancer. RIP-seq, mRNA-seq, co-immunoprecipitation/mass spectrometry, alternative splicing analysis (PSI values), functional assays Cancer letters Medium 38341127
2024 In glioma, IGF2BP3 enhances expression of E3 ubiquitin ligase MIB1, promoting FTO (m6A demethylase) degradation via the ubiquitin-proteasome pathway, resulting in increased m6A-mediated CSF3 release and NET (neutrophil extracellular trap) formation, which impedes oncolytic virus replication. Functional assays, ubiquitin-proteasome pathway analysis, m6A analysis, in vivo mouse glioma models, BET inhibitor treatment Nature communications Medium 38167409
2024 Lactylation of IGF2BP3 (driven by increased glycolysis and lactate accumulation in lenvatinib-resistant HCC) is crucial for IGF2BP3 to capture PCK2 and NRF2 mRNAs and enhance their stability. The lactylated IGF2BP3 also increases SAM availability, fueling m6A methylation of PCK2 and NRF2 mRNAs, creating a positive feedback loop that reinforces drug resistance. Lactylation assays, RIP, MeRIP, mRNA stability assays, metabolomics, in vivo lenvatinib-resistant models Advanced science Medium 39450426
2024 IGF2BP3 stabilizes HMGB1 mRNA by binding to it, promoting HMGB1 expression and bladder cancer progression; this relationship between HMGB1 mRNA and IGF2BP3 is also conserved in mammalian embryonic development where both genes decrease as development progresses. The IGF2BP3 gene is regulated by copy number gain/amplification, promoter hypomethylation, and miR-320a-3p. RIP, mRNA stability assays, bisulfite sequencing, luciferase reporter, xenograft mouse model Cellular & molecular biology letters Medium 38504159
2024 WTAP-mediated m6A modification of ULK1 mRNA enhances its stability in an IGF2BP3-dependent manner, leading to elevated ULK1 expression and enhanced mitophagy in epithelial ovarian cancer, contributing to disease progression. MeRIP, RIP, mRNA stability assays, functional mitophagy assays, in vivo tumor models Cell death & disease Medium 38286802
2024 IGF2BP3 regulates SCD mRNA m6A modifications via an IGF2BP3-METTL14 complex, enhancing SCD mRNA stability to promote lipid metabolism, proliferation, and metastasis in cervical cancer. RNA-seq, RIP assay, MeRIP, lipid droplet/TG/fatty acid assays, in vivo nude mouse model Cell death & disease Medium 38355626
2024 SENP1 mRNA 3'UTR is bound by IGF2BP3 in an m6A-dependent manner (MeRIP-qPCR and RIP-qPCR), enhancing SENP1 expression and stability in AML. IGF2BP3-stabilized SENP1 promotes AKT pathway activation via de-SUMOylation of HDAC2, which enhances EGFR transcription. CO-IP, MeRIP-qPCR, RIP-qPCR, RNA pulldown, SUMO assay, ChIP-qPCR, in vitro and in vivo AML models Molecular cancer Medium 38822351
2024 RBM15 (m6A writer) mediates m6A modification of VEGFA mRNA, which is then recognized and stabilized by IGF2BP3, leading to enhanced VEGFA expression and HUVEC tube formation/migration. Knockdown of IGF2BP3 reduces VEGFA expression and inhibits tumor angiogenesis in HCC xenograft models. MeRIP-seq, RNA-seq, CLIP-seq, RIP, cell and molecular biology validation, HCC xenograft model Molecular carcinogenesis Medium 39092767
2024 IGF2BP3 binds MYLK mRNA in an m6A-dependent manner, extending its half-life and inhibiting ERK1/2 phosphorylation, thereby repressing MSC adipogenesis. IGF2BP3 overexpression in adipose tissue (via AAV) reduces body weight and improves insulin resistance in high-fat diet mice. RIP, mRNA stability assays, m6A-dependent binding validation, ERK signaling analysis, in vivo AAV delivery, metabolic phenotyping Cellular and molecular life sciences Medium 38196046
2024 IGF2BP3 recognizes m6A on mRNAs of key serine synthesis pathway (SSP) genes (ATF4, PHGDH, PSAT1), stabilizing these transcripts and sustaining serine production to meet the metabolic demands of AML cells and leukemia stem/initiating cells. CRISPR/Cas9 screen identified that IGF2BP3 depletion sensitizes AML cells to serine/glycine deprivation; combined IGF2BP3 silencing with dietary SG restriction potently inhibits AML in vitro and in vivo while sparing normal hematopoiesis. CRISPR/Cas9 screen, RIP, mRNA stability assays, metabolomics, dietary restriction in vivo mouse models Nature communications High 40328743
2014 IGF2BP3 (IMP3) promotes trophoblast cell invasion and migration in placenta. IGF2BP3 is highly expressed in cytotrophoblast cells during early pregnancy and is reduced in the third trimester and in pre-eclamptic placentas. In vitro invasion/migration assays and ex vivo explant culture demonstrated that IGF2BP3 promotes trophoblast invasion. Immunohistochemistry in human placentas, in vitro invasion/migration assays, ex vivo explant culture model Cell death & disease Medium 24457969
2017 In CD44-positive fibroblasts, IGF2BP3 binds CD44 mRNA and enhances its expression, which increases IGF2 secretion by fibroblasts, stimulating breast cancer cell proliferation and paclitaxel resistance via Hedgehog signaling activation in breast cancer cells. Co-culture experiments, RIP for IGF2BP3-CD44 mRNA interaction, functional proliferation/drug resistance assays, Hedgehog pathway analysis Journal of cellular and molecular medicine Medium 28523716
2020 IMP3 (IGF2BP3) accelerates prostate cancer progression by increasing SMURF1 expression, which facilitates PTEN ubiquitination and degradation, activating the PI3K/AKT/mTOR signaling pathway. Immunoprecipitation/ubiquitination assays, Western blotting for PI3K/AKT/mTOR pathway, knockdown/overexpression, rescue experiments with SMURF1 silencing Journal of experimental & clinical cancer research Medium 32938489

Source papers

Stage 0 corpus · 130 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2512 14671650
2018 Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nature cell biology 2381 29476152
2012 Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 1718 22658674
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
2010 Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 1451 20881960
2011 Systematic and quantitative assessment of the ubiquitin-modified proteome. Molecular cell 1334 21906983
2016 ATPase-Modulated Stress Granules Contain a Diverse Proteome and Substructure. Cell 1233 26777405
2017 Architecture of the human interactome defines protein communities and disease networks. Nature 1085 28514442
2015 A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell 1015 26496610
2014 A proteome-scale map of the human interactome network. Cell 977 25416956
2012 The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. Molecular cell 973 22681889
2020 A reference map of the human binary protein interactome. Nature 849 32296183
2011 A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Molecular & cellular proteomics : MCP 749 21890473
2007 Large-scale mapping of human protein-protein interactions by mass spectrometry. Molecular systems biology 733 17353931
2021 Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 705 33961781
2012 A census of human soluble protein complexes. Cell 689 22939629
2011 Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 656 21873635
1999 A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Molecular and cellular biology 610 9891060
2018 High-Density Proximity Mapping Reveals the Subcellular Organization of mRNA-Associated Granules and Bodies. Molecular cell 580 29395067
2017 Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science (New York, N.Y.) 533 28302793
2013 Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nature genetics 496 23563607
2021 circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nature communications 478 33436560
2004 The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome research 438 15489334
2022 OpenCell: Endogenous tagging for the cartography of human cellular organization. Science (New York, N.Y.) 432 35271311
2010 Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science (New York, N.Y.) 421 20360068
2015 Panorama of ancient metazoan macromolecular complexes. Nature 407 26344197
2007 Systematic analysis of the protein interaction network for the human transcription machinery reveals the identity of the 7SK capping enzyme. Molecular cell 367 17643375
2020 CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal transduction and targeted therapy 366 33361760
2022 METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer. Molecular cancer 342 35197058
2021 A proximity-dependent biotinylation map of a human cell. Nature 339 34079125
2021 N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Molecular cancer 323 34416901
2010 Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell 318 21145461
2022 EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3. Molecular cancer 254 35031058
2020 Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer cell 252 31935372
2014 The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Seminars in cancer biology 236 25068994
2006 Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 218 17170732
2021 RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent. Journal of experimental & clinical cancer research : CR 203 33637103
2006 Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia 181 17170730
2020 DMDRMR-Mediated Regulation of m6A-Modified CDK4 by m6A Reader IGF2BP3 Drives ccRCC Progression. Cancer research 144 33293428
2016 RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. The Journal of clinical investigation 141 26974154
2016 CircRNA-protein complexes: IMP3 protein component defines subfamily of circRNPs. Scientific reports 129 27510448
2022 Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p. Molecular cancer 128 34986849
2020 IGF2BP3 From Physiology to Cancer: Novel Discoveries, Unsolved Issues, and Future Perspectives. Frontiers in cell and developmental biology 126 32010687
2008 The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. The American journal of surgical pathology 121 18223334
2017 IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. Molecular cancer 115 28399871
2023 Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer. Cancer research 110 37061993
2022 The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability. Experimental & molecular medicine 110 35217832
2024 Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m6A-Modification Promotes Lenvatinib Resistance in HCC. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 104 39450426
2022 IGF2BP3 is an essential N6-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells. Materials today. Bio 81 36457846
2014 IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development. Cell reports 80 24703842
2017 THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America 66 28193878
2023 A circular RNA activated by TGFβ promotes tumor metastasis through enhancing IGF2BP3-mediated PDPN mRNA stability. Nature communications 64 37898647
2019 Increased IGF2BP3 expression promotes the aggressive phenotypes of colorectal cancer cells in vitro and vivo. Journal of cellular physiology 62 30895618
2015 Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA. Oncogene 62 26522719
2017 IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor. Cancer letters 59 29217458
2023 m6 A-Dependent Modulation via IGF2BP3/MCM5/Notch Axis Promotes Partial EMT and LUAD Metastasis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 58 37171793
2021 Knockdown of m6A Reader IGF2BP3 Inhibited Hypoxia-Induced Cell Migration and Angiogenesis by Regulating Hypoxia Inducible Factor-1α in Stomach Cancer. Frontiers in oncology 58 34621671
2019 Enhancement of LIN28B-induced hematopoietic reprogramming by IGF2BP3. Genes & development 54 31221665
2022 Isoliquiritigenin inhibits non-small cell lung cancer progression via m6A/IGF2BP3-dependent TWIST1 mRNA stabilization. Phytomedicine : international journal of phytotherapy and phytopharmacology 53 35816995
2024 Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma. Nature communications 51 38167409
2023 Targeting IGF2BP3 in Cancer. International journal of molecular sciences 50 37298373
2017 CD44+ fibroblasts increases breast cancer cell survival and drug resistance via IGF2BP3-CD44-IGF2 signalling. Journal of cellular and molecular medicine 50 28523716
2014 Role of IGF2BP3 in trophoblast cell invasion and migration. Cell death & disease 50 24457969
2020 Igf2bp3 maintains maternal RNA stability and ensures early embryo development in zebrafish. Communications biology 47 32127635
2014 Oncofetal protein IMP3, a new cancer biomarker. Advances in anatomic pathology 45 24713990
2017 Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) promotes lung tumorigenesis via attenuating p53 stability. Oncotarget 44 29212181
2021 CircRNA circFOXK2 facilitates oncogenesis in breast cancer via IGF2BP3/miR-370 axis. Aging 43 34329193
2023 CircNFATC3 promotes the proliferation of gastric cancer through binding to IGF2BP3 and restricting its ubiquitination to enhance CCND1 mRNA stability. Journal of translational medicine 42 37340423
2024 IGF2BP3 promotes mRNA degradation through internal m7G modification. Nature communications 41 39198433
2023 IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m6A-dependent manner. Cell death & disease 41 37658049
2020 LINC00467 promotes cell proliferation and metastasis by binding with IGF2BP3 to enhance the mRNA stability of TRAF5 in hepatocellular carcinoma. The journal of gene medicine 40 31656043
2019 Circular RNA_101237 mediates anoxia/reoxygenation injury by targeting let‑7a‑5p/IGF2BP3 in cardiomyocytes. International journal of molecular medicine 40 31894303
2009 IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue. Human pathology 40 19698973
2021 The RNA-binding protein IGF2BP3 is critical for MLL-AF4-mediated leukemogenesis. Leukemia 38 34321607
2024 N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2. Molecular cancer 37 38822351
2022 METTL3-IGF2BP3-axis mediates the proliferation and migration of pancreatic cancer by regulating spermine synthase m6A modification. Frontiers in oncology 34 36276112
2020 Overexpression of IGF2BP3 as a Potential Oncogene in Ovarian Clear Cell Carcinoma. Frontiers in oncology 33 32083017
2020 IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way. Journal of experimental & clinical cancer research : CR 31 32938489
2023 IGF2BP3 Regulates TMA7-mediated Autophagy and Cisplatin Resistance in Laryngeal Cancer via m6A RNA Methylation. International journal of biological sciences 30 37056932
2022 RNA m6A reader IGF2BP3 promotes metastasis of triple-negative breast cancer via SLIT2 repression. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 29 36250924
2024 IGF2BP3 enhances lipid metabolism in cervical cancer by upregulating the expression of SCD. Cell death & disease 28 38355626
2024 IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development. Cellular & molecular biology letters 27 38504159
2018 Structural basis of IMP3 RRM12 recognition of RNA. RNA (New York, N.Y.) 27 30135093
2011 Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. Journal of surgical oncology 27 22012575
2014 IMP3 expression is associated with poor outcome and epigenetic deregulation in intrahepatic cholangiocarcinoma. Human pathology 26 24745619
2021 USP11 facilitates colorectal cancer proliferation and metastasis by regulating IGF2BP3 stability. American journal of translational research 25 33594305
2017 Let-7b Regulates Myoblast Proliferation by Inhibiting IGF2BP3 Expression in Dwarf and Normal Chicken. Frontiers in physiology 25 28736533
2023 Expression pattern analysis of m6A regulators reveals IGF2BP3 as a key modulator in osteoarthritis synovial macrophages. Journal of translational medicine 24 37217897
2023 IGF2BP3 promotes adult myocardial regeneration by stabilizing MMP3 mRNA through interaction with m6A modification. Cell death discovery 23 37188676
2021 IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma. Journal of cellular and molecular medicine 23 34894048
2024 Regulation of ULK1 by WTAP/IGF2BP3 axis enhances mitophagy and progression in epithelial ovarian cancer. Cell death & disease 22 38286802
2024 m6A modification of VEGFA mRNA by RBM15/YTHDF2/IGF2BP3 contributes to angiogenesis of hepatocellular carcinoma. Molecular carcinogenesis 22 39092767
2015 Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target. Oncoscience 22 26244168
2009 IMP-3 expression in melanocytic lesions. Journal of cutaneous pathology 22 19788446
2024 The IGF2BP3/Notch/Jag1 pathway: A key regulator of hepatic stellate cell ferroptosis in liver fibrosis. Clinical and translational medicine 21 39113232
2023 STRIP2 motivates non-small cell lung cancer progression by modulating the TMBIM6 stability through IGF2BP3 dependent. Journal of experimental & clinical cancer research : CR 21 36639675
2011 The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis. Journal of molecular histology 21 22042095
2024 m6A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. Clinical and translational medicine 20 38572589
2023 Parkin regulates IGF2BP3 through ubiquitination in the tumourigenesis of cervical cancer. Clinical and translational medicine 19 37877353
2018 IMP3 promotes TNBC stem cell property through miRNA-34a regulation. European review for medical and pharmacological sciences 19 29771420
2014 IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status. Journal of cancer research and clinical oncology 19 25323937
2023 circRARS synergises with IGF2BP3 to regulate RNA methylation recognition to promote tumour progression in renal cell carcinoma. Clinical and translational medicine 18 38073586
2020 Variants in PPP2R2B and IGF2BP3 are associated with higher tau deposition. Brain communications 18 33426524
2021 LINC00460 facilitated tongue squamous cell carcinoma progression via the miR-320b/IGF2BP3 axis. Oral diseases 17 33660359
2015 IMP3 expression in biopsy specimens of colorectal cancer predicts lymph node metastasis and TNM stage. International journal of clinical and experimental pathology 17 26617820
2023 IGF2BP3 Worsens Lung Cancer through Modifying Long Non-coding RNA CERS6-AS1/microRNA-1202 Axis. Current medicinal chemistry 16 35702784
2023 Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer. Frontiers in immunology 16 36761737
2023 U-shaped association between serum IGF2BP3 and T2DM: A cross-sectional study in Chinese population. Journal of diabetes 16 36891946
2023 IGF2BP3 drives gallbladder cancer progression by m6A-modified CLDN4 and inducing macrophage immunosuppressive polarization. Translational oncology 16 37643553
2021 Diagnostic value of IMP3 and p53 immunohistochemical staining in EUS-guided fine-needle aspiration for solid pancreatic tumors. Scientific reports 15 34446759
2023 Berberine promotes IGF2BP3 ubiquitination by TRIM21 to induce G1/S phase arrest in colorectal cancer cells. Chemico-biological interactions 14 36822301
2024 Circ_0098823 binding with IGF2BP3 regulates DNM1L stability to promote metastasis of hepatocellular carcinoma via mitochondrial fission. Apoptosis : an international journal on programmed cell death 13 38459420
2024 WTAP/IGF2BP3-mediated GBE1 expression accelerates the proliferation and enhances stemness in pancreatic cancer cells via upregulating c-Myc. Cellular & molecular biology letters 13 38961325
2024 m6A-modified circCREBBP enhances radiosensitivity of esophageal squamous cell carcinoma by reducing the stability of MYC through interaction with IGF2BP3. International journal of biological macromolecules 13 39653202
2019 Loss of Gsdf leads to a dysregulation of Igf2bp3-mediated oocyte development in medaka. General and comparative endocrinology 13 30951723
2025 m6A/IGF2BP3-driven serine biosynthesis fuels AML stemness and metabolic vulnerability. Nature communications 12 40328743
2025 CircABCA1 promotes ccRCC by reprogramming cholesterol metabolism and facilitating M2 macrophage polarization through IGF2BP3-mediated stabilization of SCARB1 mRNA. Molecular cancer 12 40684174
2024 IGF2BP3-mediated enhanced stability of MYLK represses MSC adipogenesis and alleviates obesity and insulin resistance in HFD mice. Cellular and molecular life sciences : CMLS 12 38196046
2023 Association of circulating tumor cells and IMP3 expression with metastasis of osteosarcoma. Frontiers in oncology 12 36937398
2022 hsa_circ_0000231 Promotes colorectal cancer cell growth through upregulation of CCND2 by IGF2BP3/miR-375 dual pathway. Cancer cell international 12 35033075
2020 The Aberrant Expression of MicroRNA-125a-5p/IGF2BP3 Axis in Advanced Gastric Cancer and Its Clinical Relevance. Technology in cancer research & treatment 12 32266868
2016 IMP-3 protects the mRNAs of cyclins D1 and D3 from GW182/AGO2-dependent translational repression. International journal of oncology 12 27840950
2013 Oncofetal protein IMP3: a new diagnostic biomarker for laryngeal carcinoma. Human pathology 12 23806529
2024 Epigenetically associated IGF2BP3 upregulation promotes cell proliferation by regulating E2F1 expression in hepatocellular carcinoma. Scientific reports 11 38992083
2024 Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade. Annals of hematology 11 39264435
2023 UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma. International journal of oncology 11 36896783
2023 IGF2BP3 aggravates lung adenocarcinoma progression by modulation of PI3K/AKT signaling pathway. Immunopharmacology and immunotoxicology 11 36972188
2023 IGF2BP3-EGFR-AKT axis promotes breast cancer MDA-MB-231 cell growth. Biochimica et biophysica acta. Molecular cell research 11 37474008
2020 IGF2BP3 (IMP3) expression in angiosarcoma, epithelioid hemangioendothelioma, and benign vascular lesions. Diagnostic pathology 11 32293476
2024 NONO promotes gallbladder cancer cell proliferation by enhancing oncogenic RNA splicing of DLG1 through interaction with IGF2BP3/RBM14. Cancer letters 10 38341127